Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
 | UCB | 7 | - | -0,94 % | |
| AB INBEV | 3 | 30 | -0,80 % | |
| ARGENX | 2 | 10 | -2,03 % | ||
| GALAPAGOS NV | 2 | 2 | +1,75 % | |
| ACKERMANS & VAN HAAREN | 2 | - | +0,11 % | |
| SYENSQO | 1 | 1 | -0,76 % | |
| SOLVAY | 1 | - | -0,64 % | |
| MELEXIS | - | 4 | +0,46 % | |
| ELIA GROUP | - | 4 | +0,24 % | |
| UMICORE | - | 2 | -1,54 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:58 | Syensqo: Frühere Solvay-Materialsparte mit durchwachsenen Zahlen | - | KunststoffWeb | ||
| 07:46 | Ackermans & Van Haaren, Delen Family Extend Historic Shareholder Agreements For 25 Years | 1 | Reuters | ||
| 07:07 | Ackermans & van Haaren and the Delen family confirm their long-term partnership with updated shareholder arrangements in respect of Delen Private Bank and Bank J. Van Breda & Co | 2 | GlobeNewswire (USA) | ||
| Mi | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| Mi | FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease | 5 | Benzinga.com | ||
| Mi | Rapid growth spurt for UCB's Bimzelx continues with hidradenitis suppurativa nod marking 5th FDA approval | 5 | FiercePharma | ||
| Mi | Anheuser-Busch investiert 14 Millionen US-Dollar in Brauerei in Houston | 3 | Investing.com Deutsch | ||
| Mi | Anheuser-Busch Invests $14 Mln In Its Houston Brewery | 2 | Reuters | ||
| Mi | Anheuser-Busch invests $14 million in Houston brewery | 3 | Investing.com | ||
| Mi | UCB gets FDA approval for Bimzelx for hidradenitis suppurativa | 4 | Seeking Alpha | ||
| Mi | UCB's BIMZELX Approved by FDA for Treatment of Adults with Hidradenitis Suppurativa | 3 | Contract Pharma | ||
| Mi | UCB Reports FDA Approval Of BIMZELX In Moderate-to-severe Hidradenitis Suppurativa | - | RTTNews | ||
| Mi | UCB's Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults | 1 | PMLiVE | ||
| Mi | UCB Receives U.S. FDA Approval for BIMZELX (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa | 74 | PR Newswire | Approval is supported by data from the two Phase 3 studies, BE HEARD I and BE HEARD II, in which BIMZELX® (bimekizumab-bkzx) improved the signs and symptoms of... ► Artikel lesen | |
| Mi | ARGENX SE - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Mi | Kepler cuts Galapagos on 'Pyrrhic gamble' strategy | 18 | Reuters | ||
| Mi | ArgenX tops BEL 20 on 'blue-sky scenario' Vyvgart progress | 8 | Reuters | ||
| Mi | Azelis strengthens Nordic market with Haarla Oy acquisition | 2 | fibre2fashion | ||
| Mi | UCB Receives US FDA Approval For Bimzelx | 7 | Reuters | ||
| Mi | argenx SE: argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies | 95 | GlobeNewswire (Europe) | Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod... ► Artikel lesen |
Seite:
1 2 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
